Immune-Related Adverse Events

Immune-related adverse events (irAEs) are the inflammatory, autoimmune-like toxicities caused by immune checkpoint inhibitors — drugs that release the natural brakes on T cells to enhance antitumour immunity. Because the same mechanism can unleash immune activity against healthy tissues, irAEs can affect almost any organ and differ in pattern, timing, and management from classic chemotherapy toxicity.

Definition

Immune-related adverse events are inflammatory toxicities arising from immune checkpoint inhibitor therapy, in which blockade of inhibitory immune pathways such as CTLA-4 or PD-1/PD-L1 produces autoimmune-like injury in normal tissues.

Scope

This topic describes how checkpoint blockade produces immune-mediated toxicity, the organ systems commonly involved (skin, gastrointestinal tract, endocrine glands, liver, lungs, and others), and the general principles of grading and recognition. It is reference material on the nature of irAEs; it does not provide immunosuppression protocols, dosing, or individualized management decisions.

Core questions

• How does checkpoint blockade lead to autoimmune-like toxicity?
• Which organ systems are most often affected by irAEs?
• How do irAEs differ from classic chemotherapy toxicity in pattern and timing?
• On what principles is irAE severity recognized and graded?

Key concepts

• Immune checkpoint inhibition (CTLA-4, PD-1/PD-L1)
• Loss of peripheral immune tolerance
• Organ-specific irAEs (dermatologic, gastrointestinal, endocrine, hepatic, pulmonary)
• Immune-mediated colitis and pneumonitis
• Endocrinopathies (e.g., thyroiditis, hypophysitis)
• Severity grading of irAEs
• Distinct timing relative to cytotoxic toxicity

Mechanisms

Immune checkpoint inhibitors block inhibitory receptors — principally CTLA-4 and the PD-1/PD-L1 axis — that normally restrain T-cell activation and maintain peripheral tolerance. By lowering these thresholds to amplify antitumour responses, the drugs can also permit T-cell-mediated attack on normal tissues, producing inflammation in skin, gut, endocrine organs, liver, lung, and other sites. The resulting injuries resemble autoimmune disease, can arise weeks to months into therapy, and may persist or recur, which distinguishes them mechanistically and temporally from the tissue damage caused by cytotoxic chemotherapy.

Clinical relevance

Recognizing that immunotherapy toxicities are immune-mediated and can involve almost any organ is essential for safe oncology practice and for interpreting the growing immunotherapy literature. This entry describes the nature and patterns of irAEs as educational reference; it is not a protocol for immunosuppression, drug interruption, or individualized care.

Epidemiology

Immune-related adverse events are common with checkpoint inhibitors and vary by agent and combination, being more frequent and often more severe with CTLA-4 blockade and with combination regimens than with PD-1/PD-L1 inhibition alone; most events are low grade, but a minority are serious and can be life-threatening.

History

The clinical success of CTLA-4 and PD-1/PD-L1 inhibitors in the 2010s transformed cancer immunotherapy and simultaneously introduced a new toxicity paradigm. As checkpoint inhibitors entered broad use, the spectrum of immune-related adverse events was characterized and professional bodies issued dedicated management guidance, establishing irAEs as a distinct category within cancer pharmacotherapy and toxicity.

Key figures

• Michael A. Postow
• Jedd D. Wolchok

Seminal works

• postow-2018
• brahmer-2018

Frequently asked questions

How are immune-related adverse events different from chemotherapy side effects?

They arise from over-activation of the immune system rather than direct cytotoxic injury, can affect almost any organ as autoimmune-like inflammation, and often appear weeks to months into treatment rather than in the immediate post-dose period.

Which organs do immune checkpoint inhibitors most commonly affect?

The skin, gastrointestinal tract, endocrine glands (such as the thyroid and pituitary), liver, and lungs are among the most frequently involved, though irAEs can occur in nearly any organ system.